JP2994037B2 - 医 薬 - Google Patents

医 薬

Info

Publication number
JP2994037B2
JP2994037B2 JP4501645A JP50164591A JP2994037B2 JP 2994037 B2 JP2994037 B2 JP 2994037B2 JP 4501645 A JP4501645 A JP 4501645A JP 50164591 A JP50164591 A JP 50164591A JP 2994037 B2 JP2994037 B2 JP 2994037B2
Authority
JP
Japan
Prior art keywords
indole
dimethylamino
methyl
ethyl
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP4501645A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06503560A (ja
Inventor
クレイグ，ジョーン
レスリー クルックス，デレク
ジョン スキットロール，スティーブン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JPH06503560A publication Critical patent/JPH06503560A/ja
Application granted granted Critical
Publication of JP2994037B2 publication Critical patent/JP2994037B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
JP4501645A 1990-12-12 1991-12-10 医 薬 Expired - Lifetime JP2994037B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9026998.6 1990-12-12
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments
PCT/EP1991/002362 WO1992010477A1 (en) 1990-12-12 1991-12-10 Medicaments

Publications (2)

Publication Number Publication Date
JPH06503560A JPH06503560A (ja) 1994-04-21
JP2994037B2 true JP2994037B2 (ja) 1999-12-27

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4501645A Expired - Lifetime JP2994037B2 (ja) 1990-12-12 1991-12-10 医 薬

Country Status (36)

Country Link
US (2) US5554639A (cg-RX-API-DMAC7.html)
EP (1) EP0490689B1 (cg-RX-API-DMAC7.html)
JP (1) JP2994037B2 (cg-RX-API-DMAC7.html)
KR (1) KR100211479B1 (cg-RX-API-DMAC7.html)
CN (2) CN1030890C (cg-RX-API-DMAC7.html)
AP (1) AP230A (cg-RX-API-DMAC7.html)
AT (1) ATE119881T1 (cg-RX-API-DMAC7.html)
AU (1) AU650706B2 (cg-RX-API-DMAC7.html)
BE (1) BE1005085A3 (cg-RX-API-DMAC7.html)
CA (1) CA2098302C (cg-RX-API-DMAC7.html)
CH (1) CH684192A5 (cg-RX-API-DMAC7.html)
CY (1) CY2005A (cg-RX-API-DMAC7.html)
CZ (1) CZ281931B6 (cg-RX-API-DMAC7.html)
DE (1) DE69108200T2 (cg-RX-API-DMAC7.html)
DK (1) DK0490689T3 (cg-RX-API-DMAC7.html)
EG (1) EG20219A (cg-RX-API-DMAC7.html)
ES (1) ES2069836T3 (cg-RX-API-DMAC7.html)
FR (1) FR2670487B1 (cg-RX-API-DMAC7.html)
GB (2) GB9026998D0 (cg-RX-API-DMAC7.html)
GR (1) GR3015430T3 (cg-RX-API-DMAC7.html)
HK (1) HK82697A (cg-RX-API-DMAC7.html)
HU (1) HU211937A9 (cg-RX-API-DMAC7.html)
IE (1) IE62894B1 (cg-RX-API-DMAC7.html)
IL (1) IL100330A (cg-RX-API-DMAC7.html)
IS (1) IS1706B (cg-RX-API-DMAC7.html)
IT (1) IT1252868B (cg-RX-API-DMAC7.html)
MX (1) MX9102501A (cg-RX-API-DMAC7.html)
MY (1) MY109265A (cg-RX-API-DMAC7.html)
NL (1) NL9102071A (cg-RX-API-DMAC7.html)
NZ (1) NZ240942A (cg-RX-API-DMAC7.html)
PT (1) PT99757B (cg-RX-API-DMAC7.html)
RU (1) RU2108328C1 (cg-RX-API-DMAC7.html)
TW (2) TW300886B (cg-RX-API-DMAC7.html)
WO (1) WO1992010477A1 (cg-RX-API-DMAC7.html)
YU (1) YU48926B (cg-RX-API-DMAC7.html)
ZA (1) ZA919750B (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0573221B1 (en) * 1992-06-05 1998-04-29 Merck Sharp & Dohme Ltd. The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US6562838B2 (en) * 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
MXPA05006954A (es) * 2002-12-26 2005-09-22 Pozen Inc Formas de dosificacion de capas multiples que contienen nsaids y triptanos.
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
WO2005119607A2 (en) * 2004-06-03 2005-12-15 Tyfone, Inc. System and method for securing financial transactions
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0610864A2 (pt) 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US8853263B2 (en) 2006-05-19 2014-10-07 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
DE602007013440D1 (de) * 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
EA020455B1 (ru) 2008-05-27 2014-11-28 Байота Сайентифик Менеджмент Пти Лтд. Бис(дигидрофосфатная) соль 6-{2-[1-(6-метил-3-пиридазинил)-4-пиперидинил]этокси}-3-этокси-1,2-бензизоксазола (1:2), способ ее получения и ее применение в композиции и способе лечения или предотвращения пикорнавирусных инфекций
EP2306998A4 (en) * 2008-06-20 2011-06-15 Alphapharm Pty Ltd PHARMACEUTICAL FORMULATION
CA2729056A1 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
EP2296652B1 (en) * 2008-06-30 2017-11-08 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
NZ599344A (en) 2009-09-25 2015-02-27 Reddy’S Lab Ltd Dr Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
WO2016141056A1 (en) 2015-03-02 2016-09-09 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
JP6897971B2 (ja) 2015-05-15 2021-07-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 関節炎を処置するための、方法および組成物
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
MX2020004566A (es) 2017-11-07 2020-08-13 Univ Michigan Regents Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso.
US20220096438A1 (en) 2018-09-07 2022-03-31 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
CN115335051A (zh) * 2020-02-27 2022-11-11 拜尔哈文制药股份有限公司 瑞美吉泮的口服快速分散型剂型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
MX9102501A (es) 1992-09-01
EP0490689A1 (en) 1992-06-17
GR3015430T3 (en) 1995-06-30
US5705520A (en) 1998-01-06
AU650706B2 (en) 1994-06-30
AU9072091A (en) 1992-07-08
ES2069836T3 (es) 1995-05-16
EP0490689B1 (en) 1995-03-15
DE69108200T2 (de) 1995-07-20
TW205035B (cg-RX-API-DMAC7.html) 1993-05-01
GB9126297D0 (en) 1992-02-12
US5554639A (en) 1996-09-10
NL9102071A (nl) 1992-07-01
DE69108200D1 (de) 1995-04-20
FR2670487B1 (fr) 1993-08-20
IS1706B (is) 1998-12-10
CY2005A (en) 1997-12-05
IL100330A (en) 1996-06-18
PT99757B (pt) 1999-05-31
FR2670487A1 (fr) 1992-06-19
KR100211479B1 (ko) 1999-08-02
DK0490689T3 (da) 1995-05-22
CH684192A5 (fr) 1994-07-29
IL100330A0 (en) 1992-09-06
ITRM910922A0 (it) 1991-12-11
EG20219A (en) 1997-11-30
CA2098302C (en) 2001-10-16
IE62894B1 (en) 1995-03-08
MY109265A (en) 1996-12-31
BE1005085A3 (fr) 1993-04-13
IS3790A7 (is) 1992-06-13
CZ114093A3 (en) 1994-02-16
PT99757A (pt) 1992-12-31
AP9100339A0 (en) 1992-01-31
ATE119881T1 (de) 1995-04-15
GB2251614B (en) 1994-12-14
HU211937A9 (en) 1996-01-29
ZA919750B (en) 1992-10-28
CA2098302A1 (en) 1992-06-13
YU191491A (sh) 1994-04-05
RU2108328C1 (ru) 1998-04-10
CN1050831C (zh) 2000-03-29
NZ240942A (en) 1994-03-25
AP230A (en) 1993-01-27
TW300886B (cg-RX-API-DMAC7.html) 1997-03-21
GB9026998D0 (en) 1991-01-30
HK82697A (en) 1997-06-27
CZ281931B6 (cs) 1997-04-16
IT1252868B (it) 1995-06-28
JPH06503560A (ja) 1994-04-21
IE914317A1 (en) 1992-06-17
GB2251614A (en) 1992-07-15
YU48926B (sh) 2002-12-10
CN1063099A (zh) 1992-07-29
CN1128259A (zh) 1996-08-07
WO1992010477A1 (en) 1992-06-25
CN1030890C (zh) 1996-02-07
ITRM910922A1 (it) 1993-06-11

Similar Documents

Publication Publication Date Title
JP2994037B2 (ja) 医 薬
US5393773A (en) Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide
RU2130022C1 (ru) N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство
US5834502A (en) Triazolylmethyl-indole ethylamine bisulfate salt
CN102933198B (zh) 包含曲普坦化合物的制剂
EP0840733B1 (en) A triazolylmethyl-indole ethylamine bisulfate salt
NO179102B (no) 3-[2-(dimetylamino)etylÅ-N-metyl-1H-indol-5-metansulfonamid